Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

NCT04156087 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer Non-resectable

Interventions

DRUG: Durvalumab 50 MG/ML
DRUG: Tremelimumab
DRUG: Gemcitabine
PROCEDURE: Minimally Invasive Surgical Microwave Ablation (MIS-MWA)

Sponsor

Baki Topal

Collaborators

[object Object]